Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 55

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2018

Summary

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) pipeline Target constitutes close to 8 molecules. The latest report Ileal SodiumBile Acid Cotransporter - Pipeline Review, H1 2018, outlays comprehensive information on the Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Ileal Sodium/Bile Acid Co-transporter is encoded by SLC10A2 gene. It plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine and cholesterol metabolism. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Dermatology, Genetic Disorders and Metabolic Disorders which include indications Non-Alcoholic Steatohepatitis (NASH), Cholestasis, Primary Sclerosing Cholangitis, Alagille Syndrome, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis, Pruritus, Biliary Atresia, Liver Diseases and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)

- The report reviews Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Overview
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Companies Involved in Therapeutics Development
Albireo Pharma Inc
CJ HealthCare Corp
GlaxoSmithKline Plc
Shire Plc
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-14199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit IBAT for Liver and Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Dormant Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Discontinued Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Product Development Milestones
Featured News & Press Releases
May 28, 2018: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" Will Be Presented at DDW2018
May 16, 2018: Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250
Apr 19, 2018: World's First Bile Acid Transporter Inhibitor GOOFICE 5mg Tablet Launched in Japan
Apr 19, 2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
Apr 14, 2018: Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at the International Liver Congress 2018
Mar 28, 2018: Albireo to Present Clinical Data on A4250 at The International Liver Congress 2018
Jan 19, 2018: New drug approval of bile acid transporter inhibitor "GOOFICE 5mg Tablet "for chronic constipation was obtained in Japan
Oct 20, 2017: Final Results of Albireo's Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting 2017
Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017
Sep 26, 2017: EMA's Pediatric Committee Agrees to Albireo's A4250 Pediatric Investigation Plan
May 18, 2017: Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
May 16, 2017: Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
Apr 27, 2017: Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017
Apr 22, 2017: Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress 2017
Apr 05, 2017: EASL Selects Albireo's A4250 Data for Late Breaker Presentation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Albireo Pharma Inc, H1 2018
Pipeline by CJ HealthCare Corp, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Shire Plc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • 2018-2023 Global PEGylated Proteins Consumption Market Report
    Published: 15-Jun-2018        Price: US 4660 Onwards        Pages: 138
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global PEGylated Proteins market for 2018-2023. PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s. The threat of substitutes arises when there a......
  • 2018 Top 5 PEGylated Proteins Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 15-Jun-2018        Price: US 4960 Onwards        Pages: 125
    PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s. The threat of substitutes arises when there are similar products developed by competitors which satisfy the market needs. When consumers have access to substitute products which can satisfy their market needs, then manufacturer......
  • 2018-2023 Global Erythropoietin Consumption Market Report
    Published: 15-Jun-2018        Price: US 4660 Onwards        Pages: 131
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Erythropoietin market for 2018-2023. Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adult......
  • 2018 Top 5 Erythropoietin Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 15-Jun-2018        Price: US 4960 Onwards        Pages: 125
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, t......
  • Global Enzymatic Debridement Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Enzymatic Debridement Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 133
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, By End User, Companies
    Published: 14-Jun-2018        Price: US 1990 Onwards        Pages: 355
    Global Vaccine Market is projected to reach US$ 70 Billion by the year 2024. The vaccine market is likely to witness a significant growth throughout the forecast period due to the growing prevalence of diseases, increasing government and non-government funding for vaccine development & distribution and increasing investments by companies to develop new vaccines. Furthermore, growing demand for preventive vaccines, rising consciousness about vaccination coupled with mounting demand from th......
  • Global Celery Seed Extract Solid Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 13-Jun-2018        Price: US 3480 Onwards        Pages: 135
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Celery Seed Extract Solid Market 2018, Forecast to 2023
    Published: 13-Jun-2018        Price: US 4880 Onwards        Pages: 128
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs